Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]

Irinotecan hydrochloride (CPT-11) shows marked anti-tumour activity alone and in combination with cisplatin in non-small-cell lung cancer (NSCLC). It is necessary to investigate combined-modality therapy including novel effective anti-cancer agents to improve long-term survival of patients with unre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, A., Kurita, Y., Saijo, N., Tamura, T., Noda, K., Shimokata, K., Matsuda, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062904/
https://www.ncbi.nlm.nih.gov/pubmed/9683303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062904/
https://www.ncbi.nlm.nih.gov/pubmed/9683303

Ejemplares similares